Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca's Tagrisso gets China OK for type of lung cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 04:26am EDT
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, England

(Reuters) - AstraZeneca Plc said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.

China approved Tagrisso as a first-line treatment for adults with non-small cell lung cancer patients whose tumours have certain genetic mutations, AstraZeneca said.

Last month, the British drugmaker said a late-stage study showed Tagrisso had significantly helped patients with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer live longer.

The company has moved deeper into cancer therapy through wide-ranging deals, including those for immunotherapy and targeted therapy. Earlier this year, it agreed to a multi-billion dollar oncology deal with Japan's Daiichi Sankyo Co.

Sales from AstraZeneca's oncology unit soared 57% to $2.17 billion in the second quarter, accounting for 38% of total product sales, with revenue from Tagrisso nearly doubling to $784 million.

AstraZeneca had also raised its product sales forecast for 2019, thanks in part to strong sales of cancer drugs.

(This story corrects to show study in August points to overall survival and not progression free survival in paragraph three)

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Bernard Orr)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 1.96% 6927 Delayed Quote.15.66%
DAIICHI SANKYO COMPANY, LIMITED 0.20% 6939 End-of-day quote.102.60%
SANKYO CO., LTD. 1.48% 3775 End-of-day quote.-5.15%
SEVEN & I HOLDINGS CO., LTD. 0.81% 4109 End-of-day quote.-14.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
04:56aLondon's blue-chip index gains ground; Sirius Minerals sinks
RE
09/16ASTRAZENECA : FDA Grants Fast Track Designation for Farxiga in Heart Failure
DJ
09/16ASTRAZENECA : redefines cancer treatment with practice-changing data at ESMO 201..
PU
09/16ASTRAZENECA : FDA grants Fast Track designation for Farxiga in heart failure
PU
09/10LONDON STOCK EXCHANGE : JD Sports leads FTSE 100 higher, rate cut hopes support
RE
09/09UK bluechips give up gains as sterling strengthens
RE
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both significant survival b..
PU
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both
PU
09/09ASTRAZENECA : Imfinzi Shows Efficacy in Treating Small-Cell Lung Cancer
DJ
09/09ASTRAZENECA : Imfinzi is first immunotherapy to show both significant survival b..
AQ
More news
Financials (USD)
Sales 2019 23 966 M
EBIT 2019 6 383 M
Net income 2019 2 301 M
Debt 2019 11 471 M
Yield 2019 3,31%
P/E ratio 2019 47,3x
P/E ratio 2020 34,1x
EV / Sales2019 5,10x
EV / Sales2020 4,65x
Capitalization 111 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 93,28  $
Last Close Price 84,41  $
Spread / Highest target 53,6%
Spread / Average Target 10,5%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA15.66%110 661
JOHNSON & JOHNSON1.34%341 878
ROCHE HOLDING LTD.12.28%234 825
MERCK AND COMPANY7.36%210 028
PFIZER-15.62%203 709
NOVARTIS16.65%198 073